Clinical trial NCT04433494: A Study of TY-302 in Patients With Advanced Solid Tumors
Official title: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of TY-302 Capsules in Patients With Advanced Solid Tumors in China
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Breast Cancer
Solid Tumor
Lead sponsor: TYK Medicines, Inc
Sponsor class: INDUSTRY
First posted: 2020-06-16
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to evaluate the safety and tolerability of TY-302 single and the combination with Tamoxifen in dose-escalation and dose-expansion study.The drugs involved in this study are:

* TY-302
* Tamoxifen

Detailed description: This is an open-label, single-arm, phase I trial. The purpose of this study is to :

* Test a safe and tolerable dose of TY-302 single and the combination with Tamoxifen
* Determine the response rate of the combination
* Further evaluate the safety and side effect profile for the combination of TY-302 and Tamoxifen.

Eligibility criteria: Inclusion Criteria:

1. 18-70years old, male or female with solid tumors, female with breast cancer
2. Histological or cytological confirmation diagnosis of advanced solid tumors (except small cell lung cancer and eye cancer) in TY-302 alone study; and advanced breast cancer in the combination study.
3. Biopsy proven diagnosis of ER and/or PR positive, HER2 negative.
4. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
5. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
6. Life expectancy of at least 3 month.
7. Adequate organ function as defined by the following criteria:

   Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤2.5 x upper limit of normal (ULN), or AST and ALT ≤5 x ULN if liver function abnormalities are due to underlying malignancy; total serum bilirubin ≤1.5 x ULN; Absolute neutrophil count (ANC) ≥1.5×109/L; platelets(PLT)≥75×109/L ; Hemoglobin(Hb) ≥ 90g/L; Serum creatinine ≤1.5 x ULN; Left ejection fraction (LVEF)≥50%; QTc≤470 msec (based on the mean value of the triplicate ECGs).
8. Female subjects have a negative urine or serum pregnancy.
9. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.

Exclusion Criteria:

Subjects presenting with any of the following were not to be included in the study:

1. Previously treated by other CDK4/6 inhibitor.
2. Hypersensitivity to TY-302(or Tamoxifen in the combination study) or to any of its excipients.
3. Ocular fundus diseases in the combination study.
4. Uncontrolled intercurrent illness including active infection, human immunodeficiency virus infection, active hepatitis or other severe acute or chronic medical or psychiatric condition.
5. Current alcohol/drug abuse or dependence.
6. Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE grade≥2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure of NCI CTCAE grade≥2, cerebrovascular accident.
7. Presence of a condition that would interfere with enteric absorption of TY-302 and/or Tamoxifen.
8. Any cytotoxic chemotherapy, investigational agents or anticancer drugs for the treatment from a previous treatment regimen within 4 weeks of the first dose.
9. Spinal cord compression or brain metastases unless asymptomatic.
10. Major surgery within 8 weeks of first study treatment.
11. Current use or anticipated need for drugs that are known strong CYP3A4 inhibitors, strong CYP3A4 inducers, Narrow therapeutic index for CYP3A sensitive substrates, CYP2D6 inhibitors, CYP2D6 inducers.
12. Patients on chronic anticoagulation.
13. The subject inappropriate for entry into this study in the judgment of the investigator.

Primary outcomes:
measure: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TY-302
timeFrame: 1 year
measure: Dose Limiting Toxicity (DLT) of TY-302
timeFrame: First 35 days of dosing
measure: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TY-302 combine with Tamoxifen
timeFrame: 1 year
measure: Dose Limiting Toxicity (DLT) of TY-302 combine with Tamoxifen
timeFrame: First 28 days of dosing
measure: Overall Response Rate (ORR) of TY-302 combine with Tamoxifen
timeFrame: 6 months
measure: Disease Control Rate(DCR) of TY-302 combine with Tamoxifen
timeFrame: 9 months
measure: Duration of Response (DOR) of TY-302 combine with Tamoxifen
timeFrame: 9 months
measure: Progression-free Survival (PFS) of TY-302 combine with Tamoxifen
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese Academy of Medical Sciences and Peking Union Medical Colledge
state: Beijing
Study officials:
affiliation: Chinese Academy of Medical Sciences and Peking Union Medical Colledge
name: Binghe Xu, MD
role: PRINCIPAL_INVESTIGATOR
References: